Mirasol Evaluation of Reduction in Infections Trial (MERIT)
Randomized Trial to Evaluate Mirasol Whole Blood Pathogen Reduction Technology System to Reduce Malaria and Emerging Transfusion Transmitted Infections
Sponsor: Johns Hopkins University
Listed as NCT03737669, this PHASE3 trial focuses on Transfusion-Transmitted Infectious Disease and remains completed. Sponsored by Johns Hopkins University, it has been updated 14 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Nov 2024 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 9 earlier versions
-
Nov 2022 — Nov 2023 [monthly]
Recruiting PHASE3
-
Nov 2021 — Nov 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Dec 2019 — Dec 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE3
-
May 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
- MU-JHU CARE
- Terumo BCT
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .